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Abstract
The genetic architecture of ischemic stroke is complex and is likely to include rare or low frequency variants with high
penetrance and large effect sizes. Such variants are likely to provide important insights into disease pathogenesis compared
to common variants with small effect sizes. Because a significant portion of human functional variation may derive from the
protein-coding portion of genes we undertook a pilot study to identify variation across the human exome (i.e., the coding
exons across the entire human genome) in 10 ischemic stroke cases. Our efforts focused on evaluating the feasibility and
identifying the difficulties in this type of research as it applies to ischemic stroke. The cases included 8 African-Americans
and 2 Caucasians selected on the basis of similar stroke subtypes and by implementing a case selection algorithm that
emphasized the genetic contribution of stroke risk. Following construction of paired-end sequencing libraries, all predicted
human exons in each sample were captured and sequenced. Sequencing generated an average of 25.5 million read pairs
(75 bp62) and 3.8 Gbp per sample. After passing quality filters, screening the exomes against dbSNP demonstrated an
average of 2839 novel SNPs among African-Americans and 1105 among Caucasians. In an aggregate analysis, 48 genes were
identified to have at least one rare variant across all stroke cases. One gene, CSN3, identified by screening our prior GWAS
results in conjunction with our exome results, was found to contain an interesting coding polymorphism as well as
containing excess rare variation as compared with the other genes evaluated. In conclusion, while rare coding variants may
predispose to the risk of ischemic stroke, this fact has yet to be definitively proven. Our study demonstrates the complexities
of such research and highlights that while exome data can be obtained, the optimal analytical methods have yet to be
determined.
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Introduction
Stroke is the fourth leading cause of death and the leading cause
of disability in the US [1], requiring expenditures near $70 billion
annually [2]. Stroke prevention and treatment efforts are
hampered by a lack of understanding of the basic etiologic
mechanisms. Even in clinically well-defined stroke subtypes such
as lacunar stroke, the genetic architecture remains uncertain and
could be determined by common variants with small effect sizes,
rare variants with large effect sizes, or a combination of common
and rare variants. The genome-wide association (GWA) approach
is designed to detect common disease-associated variants, but is
not designed to detect rare variants that occur infrequently in the
population or private to the affected individual. The rare variant
hypothesis posits that multiple rare variants, within the same gene
or pathway, may lead to disease. Identification of rare variants
may lead to critically important insights about disease etiology
through implication of new genes and/or pathways. At this time
full-genome sequencing remains cost prohibitive; however, the
genetic variation in the protein-coding portion of genes can be cost
effectively studied and is of significant interest in the study of
human health. The ‘exome’, or coding exons, are thought to
harbor a significant portion of human functional variation and
contain many rare variants of high penetrance. The human exome
refers to the 1% of the human genome that codes for proteins and
consists of approximately 50 Mb covering ,25,000 genes and
includes both exons and microRNAs [3]. Our focus on the exome
is based upon the belief that the exome harbors a significant
portion of human functional variation. Variation within the exome
is responsible for most Mendelian diseases, primarily mutations
that cause amino acid substitutions, including changes to nonsense
codons (,60%) [4,5], but also small indels (insertions/deletions) in
genes (,25%).
Rare variants and disease
Several studies have successfully employed exome sequencing to
identify rare mutations that are responsible for Mendelian disease.
In a proof-of-principle study, four affected individuals with
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2010 July) and eight HapMap controls underwent exome were
sequencing to demonstrate that that this technique could identify
the known mutations in the MYH3 gene that cause the disease [6].
In another study, exome sequencing identified the previously
unknown causative gene DHODH for Miller Syndrome (OMIM:
#263750 - accessed 2010 July), a rare autosomal recessive
Mendelian disease characterized by an under-sized jaw, droopy
eyes, cleft lip or palate, and incomplete or unusual limb
development [7].
While these examples demonstrate the usefulness of the exome
approach in identifying rare variants associated with Mendelian
disease, other studies are now revealing the role of rare variants in
complex disease. In one such study, rare variants were determined
to be associated with development of the well-established complex
disease of hypertension [8]. In this study, investigators evaluated
for the presence of rare loss-of-function mutations in genes coding
for transporter proteins involved in renal sodium handling.
Deficient homozygotes develop rare Mendelian disorders known
as Gitelman’s (OMIM: #263800 - accessed 2010 July) and
Bartter’s (OMIM: #607364 - accessed 2010 July) syndromes,
both of which are characterized by low blood pressures. The
investigators demonstrated that heterozygote mutation carriers
had significantly lower mean long-term values for systolic
(26.3 mm Hg; p=0.0009) and diastolic (23.4 mm Hg;
p=0.003) BP and a 59% (95% confidence interval: 23% to
71%; p,0.003) lower risk of developing hypertension by age 60
years. In summary, individuals in the lower blood pressure ‘tail’ of
the overall blood pressure distribution were found to have rare
coding genetic variants influencing renal salt handling that
contributed to blood pressure variation at the population level.
Young-onset stroke is well suited for studies of the
exome to identify rare variants
Various studies of complex diseases indicate that young onset
disease is more likely due to multiple rare exonic variants with
large effects as compared to late-onset disease. As an example,
studies identified rare mutations in the parkin gene in the PARK2
locus that cause sporadic early-onset parkinsonism [9]. Subse-
quently, other studies identified other parkin variants that play a
role in the common late-onset forms of Parkinson disease (age of
onset .45 years) [10]. Hence, identification of rare mutations in
genes that cause early-onset disease can identify genes associated
with the more common, later-onset form of the disease.
Regarding stroke, twin studies and familial aggregation studies
suggest a stronger genetic contribution to early onset than later
onset stroke. Reports from the National Academy of Sciences-
National Research Council Twin Registry showed a greater
concordance in monozygotic twins relative to dizygotic twins when
the twin cohort was younger [11,12] Evidence from prior research,
including meta-analyses [13], has consistently supported a greater
degree of familial aggregation and a greater inherited component
of stroke among early-onset compared to late-onset ischemic
stroke cases. These findings were replicated using our own young
stroke dataset, which demonstrated that siblings of stroke cases had
more than four times the risk of stroke compared to siblings of
controls (OR, 4.17; 95% CI, 1.9 to 8.8) and mothers of stroke
cases had twice the risk of stroke compared to mothers of controls
(OR, 2.02; 95% CI, 1.4 to 3.0) [14]. Furthermore, the association
between stroke in probands and family history of stroke was
strongest among women ages 15–24 years (OR, 2.5; 95% CI, 0.4
to 15.1), and diminished with increasing proband age, (OR, 1.6;
95% CI, 0.8 to 3.3 among women 25–34 yrs and OR, 1.5; 95%
CI, 1.1 to 1.9 among women 35–49 yrs). Taken in aggregate, the
evidence supports the point of view that the extreme disease
phenotype, young age-of-onset stroke, has more familial aggrega-
tion and is likely more genetically driven than later onset forms of
the disease.
In summary, this background information demonstrates the
usefulness of the exome approach in identifying rare variants
associated with Mendelian disease and also implies that by
studying individuals in the extreme phenotypic tails in common
complex disease, one can identify rare variants that have
population-level effects on disease risk. While young-onset stroke
is clearly not a Mendelian transmitted disease, rare variants of high
penetrance could conceivably contribute to risk among the young-
onset stroke phenotype. As such, a young age-of-onset can be
considered as an extreme tail of the liability threshold distribution
which is also often a characteristic of Mendelian disease. In this
report, we describe our pilot study efforts to identify rare variants
associated with ischemic stroke and the complexities of such
research. We believe that sequencing will ultimately identify rare
risk variants and that exome sequencing, given its ability to
identify rare variants of high penetrance, is an excellent
methodology to begin these efforts.
Methods
Ethics Statement
All human subjects research presented herein has been reviewed
and approved by the Institutional Review Boards of the University
of Maryland and the Mayo Clinic. Written informed consent was
obtained from all participants involved in the study.
Source study populations
Ten ischemic stroke subjects were selected for exome sequenc-
ing and analyses; 8 African-American participants from the
Genetics of Early Onset Stroke Study and 2 European-Caucasian
participants from the Siblings with Ischemic Stroke Study.
Genetics of Early Onset Stroke (GEOS) Study
GEOS is a population-based study of ischemic stroke among
Caucasian and African-American young adults in the Baltimore-
Washington area that is composed of patients and controls
recruited in 3 different time periods: Stroke Prevention in Young
Women-1 (SPYW-1) conducted from 1992–1996, Stroke Preven-
tion in Young Women-2 (SPYW-2) conducted from 2001–2003,
and Stroke Prevention in Young Men (SPYM) conducted from
2003–2007. The study population (see Table 1) has slightly more
men than women, and slightly more Caucasians than African-
Americans.
Case participants were hospitalized with a first cerebral infarction
identified by discharge surveillance from one of 59 hospitals in the
greater Baltimore-Washington area and direct referral from
regional neurologists. SPYW-1 included cases ages 15–44 years
recruited within one year of stroke and was designed with a 1:2
case-to-control ratio. SPYW-2 and SPYM included cases ages 15–
49 recruited within three years of stroke and was designed with a
1:1 case-to-control ratio. The abstracted hospital records of cases
were reviewed and adjudicated for ischemic stroke subtype by a
pair of neurologists according to previously published procedures
[15], with disagreements resolved by a third neurologist. The
ischemic stroke subtype classification system retains information
on all probable and possible causes, and is reducible to the more
widely used TOAST [16] system that assigns each case to a single
category. Monongenetic forms of stroke were excluded with
further exclusions based upon the criteria used in the Siblings With
Rare Variants in Ischemic Stroke
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classification for GEOS cases can be seen in Table 1.
Control participants without a history of stroke were identified by
random-digit dialing. Controls were balanced to cases by age and
region of residence in each study and were additionally balanced
for ethnicity in SPYW-2 and SPYM.
For both cases and controls risk factors including hypertension,
diabetes mellitus, and myocardial infarction were determined by
asking the study participant (or his/her proxy if the participant was
unable to answer) if he/she had ever been told by a physician that
he/she had the condition. Similarly, age, race, ethnicity, oral
contraceptive use, and smoking history were determined by
subject or proxy report. Less than 5% of participants had proxy
interviews or assisted interviews. Cigarette smoking information
included: ever smoker, current smoker, former smoker, number of
years smoking, average number of cigarettes smoked during
smoking years, and pack-years of smoking. (See Table 1).
Siblings with Ischemic Stroke Study (SWISS)
The aim of SWISS was to test the hypothesis that the human
genome contains chromosomal regions associated with ischemic
stroke by means of genome-wide scanning in DNA samples
collected from 300 sibling pairs concordant for ischemic stroke and
from 200 discordant siblings [17]. DNA collection began October
of 2000 with the trial completed in 2010. Analyses are ongoing.
The population study consists of three classes of participants
including: probands, concordant siblings, and discordant siblings -
each with their own inclusion and exclusion criteria. Probands
were required to experience at least one ischemic stroke episode
confirmed by either head CT or MRI completed within 7 days of
symptom onset. In addition they were required to have at least one
living full sibling with a history of ischemic stroke. There is no time
limit on how long ago the stroke may have occurred in the
sibling(s). Concordant siblings were required to have at least one
radiographically-verified ischemic stroke episode, in addition to
one living full sibling enrolled as a proband in SWISS. Discordant
siblings were required to have no history of ischemic stroke,
transient ischemic attack (TIA), or stroke symptoms, and must
have at least two full siblings with a history of ischemic stroke who
were enrolled in SWISS.
Exclusion Criteria. Patients whose strokes occurred within
48 hours of an invasive cerebrovascular or cardiovascular
procedure, a catheter-based procedure on carotid or coronary
arteries, carotid endarterectomy, heart valve surgery, or thoracic or
thoracoabdominal aortic aneurysm repair, whose ischemic strokes
occur within 60 days of nontraumatic subarachnoid hemorrhage
(SAH), who have had brain-biopsy-proven central nervous system
vasculitis at any time, who have Cerebral Autosomal Dominant
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
(CADASIL), Fabry disease, homocystinuria, mitochondrial
encephalopathy with lactic acidosis and stroke-like episodes
(MELAS), or sickle -cell anemia, or who had a mechanical aortic
or mitral valve, or bacterial endocarditis at the time of stroke onset,
were excluded from the Proband and Concordant Sibling groups.
Patients who gave a positive answer to any of the 8 questions on the
Questionnaire for Verifying Stroke-Free Status (QVSFS), or who
deemed unreliable historians by the study interviewer due to
moderate or severe impairment of speech, language, hearing, or
memory, were be excluded from the Discordant Sibling group.
Patient Involvement. Probands: Prior to enrollment,
patients’ medical records and test results were reviewed by a
study neurologist to confirm the diagnosis of ischemic stroke.
Eligible patients were classified by stroke subtype, according to the
TOAST criteria [16]. Probands then mailed invitations to
participate in SWISS to their siblings. Discordant Siblings:
Persons who responded positively to the SWISS invitation were
given a Questionnaire for Verifying Stroke-Free Status (QVSFS)
and a brief medical history was obtained via telephone interview.
Patients who receive a QVSFS score .0 were considered for
inclusion in the Concordant Siblings group. Concordant Siblings:
Persons who respond positively to the SWISS invitation had their
medical records requested and reviewed by investigators in order
to verify the stroke diagnosis. Once an eligible proband had at
least one verified concordant sibling, blood was collected by a
home health care agency from all enrolled family members for
genetic analysis.
Exome Pilot Study Population
Considerable thought was given as to which ten cases to include
in our analyses, as the goal of this pilot was to not only to
demonstrate the effective use of exome methodologies, but that
these exomes would then also be combined with additional future
exomes for further analyses. Additionally, future collaborative
efforts between the GEOS and SWISS studies were also
considered. Having two SWISS European-Caucasian samples
run on the University of Maryland platform and through the
bioinformatics pipeline would allow for future quality control
evaluations on SWISS samples undergoing exome sequencing
elsewhere.
As described in the Introduction, prior successes to identify
causative disease variants implementing exome analyses have
centered on the use of a highly defined phenotype. Given the
heterogeneity of stroke and numerous stroke subtypes, each of
which might be considered as a separate complex disease,
implementing this methodology in our stroke population was
somewhat more difficult. In an effort to maximize the genetic
contribution to stroke risk, we limited our case selection to only
one gender (male), cases with an early age-of-onset, a positive
family history of stroke, and the presence of no (or minimal)
standard stroke risk factors. We also worked to limit the stroke
Table 1. GEOS population characteristics by case-control
status.
Cases(n=889) Controls(n=927) P-value
Age (mean 6 SD, years) 41.366.9 39.666.8 ,0.001
Female (%) 41.5 43.6 0.37
Self-reported race (%) 0.22
European ancestry 52.42 56.42
African ancestry 42.41 38.51
Others 5.17 5.07
TOAST Subtype (%) --- ---
Cardioembolic 20.0
Large Artery 7.1
Lacunar 16.1
Other Known Causes 6.5
Undetermined Causes 50.3
Hypertension (%) 42.7 19.2 ,0.001
Diabetes mellitus (%) 16.7 5.1 ,0.001
Angina/MI (%) 5.3 0.7 ,0.001
Current smokers (%) 42.5 28.6 ,0.001
doi:10.1371/journal.pone.0035591.t001
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would have been the optimal methodology. As seen in Table 2,
the 10 stroke cases included 8 African-Americans (from GEOS)
and 2 European-Caucasians (SWISS samples); the TOAST
subtypes included 5 lacunar, 2 cryptogenic, 2 dissection, and 1
cardioembolic stroke.
Existing GWAS data
Here we briefly describe our recently completed GWAS on the
GEOS study population, as some of these results were utilized to
inform on our exome analyses. Our group recently implemented
the Illumina 1 M Quad GWAS chip on the GEOS population
(including the 8 GEOS exome samples). The SNPs included on
this chip were chosen based upon allele frequencies greater than
5% within HapMap datasets; therefore, rare variants were
specifically excluded. Following extensive data cleaning proce-
dures, GWAS analyses were performed with a manuscript
detailing these results recently published [18]. To summarize, we
genotyped 1 million SNPs in our biracial GEOS population
consisting of 889 ischemic stroke cases and 927 control subjects,
aged 15–49 years, and imputed up to approximately 1.4 millions
SNPs using HapMap3 reference panel to test their associations
with stroke risk using logistic regression models adjusting for age,
recruitment stages and population structure. We did not identify
any associations that achieved stringent genome-wide significance.
The most strongly associated SNPs were rs2304556 (P=1.18610-
7) in the intron of FMNL2 (HGNC:18267), which encodes a
formin-related protein, and rs1986743 (P=2.65610-7) in the
intron of ARL6IP6 (HGNC:24048), which encodes ADP-ribosyla-
tion-like factor 6 interacting protein 6. As such, no SNP attained
genome wide significance in our modestly-sized GWAS, support-
ing the notion that a few common variants do not account for the
majority of stroke risk.
Having GWAS data on our exome cases allowed us to assess
and compare genotype calls from a quality control standpoint (see
Table S1). Also, as related to our future plans, GWAS data from
these same study subjects can be utilized to select the optimal
control subjects from other pre-existing publically available exome
controls samples (e.g. NHLBI GO ESP available at dbGAP) to
minimize confounding secondary to admixture.
The GWAS data used in these analyses is available at database
of Genotypes and Phenotypes (dbGaP) (http://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id=phs000292.v1.p1;
dbGaP Study Accession: phs000292.v1.p1 - accessed 2012
January).
Exome Sequencing Methodology
Sequencing libraryconstruction,exomecapture,sequencing,and
initial analyses for our study was performed by the Genomics
Resource Center (GRC) within the Institute for Genome Sciences
(IGS) at the University of Maryland School of Medicine.
Construction of paired-end Illumina sequencing libraries were
performed as prescribed by the manufacturer. These libraries will
include unique 6 bp index sequences to enable multiplexed
sequencing of more than one library per flowcell lane. Following
library construction, Agilent’s SureSelect technology was utilized to
target capture ofall predictedhuman exonsineachsample forhigh-
throughput sequencing using the Illumina Genome Analyzer IIx
(GAIIx) platform. The method utilizes custom-designed, biotiny-
lated RNA oligonucleotides for hybridization to the target sequence
[19]. We implemented the Human All Exon kit using 120-mer baits
designed to tile across more than 37 Mbp of human genomic
sequence, including all CDS-annotated and GENCODE exons and
more than one thousand additional non-coding RNAs [3].
Following hybridization of library fragments to the RNA baits,
the bound fragments were captured by streptavidin-coated
magnetic beads, and unbound fragments were washed away.
The RNA was then digested, leaving captured library fragments
ready for sequencing. The captured library fragments were
sequenced using an Illumina Genome Analyzer IIx. We sequenced
100 bp from both ends of each library fragment. Each lane of
Illumina GAIIx sequencing generated 80–100 million high-
quality, passed-filter sequence read pairs. Of these, approximately
75% were uniquely mappable reads with an estimated 70–90% of
the uniquely mappable reads falling on or within 200 bp of a
targeted exon. This sequence coverage yielded at least 206
sequence coverage for more than 75% of targeted exons, leading
to high confidence SNP calls with low false positive rates [3,20].
In addition to performing the exome capture and sequencing,
the Genomics Resource Center provided bioinformatics support
for the project. Raw data from the sequencer was processed using
Illumina’s RTA and CASAVA pipeline software, which includes
image analysis, base calling, and sequence quality scoring, as well
as pre-existing GRC-developed pipelines for sequence assessment
and quality control. Following basecalling by Illumina pipelines,
the quality control pipeline assessed basecall quality, converted
Illumina quality scores (ASCII+64) to Sanger-style/Phred-like
scores (ASCII+32) and truncated reads where the median Phred-
like quality score fell below Q20. The pipeline also plotted base
composition by cycle/position to identify potential cycles with
aberrant chemistry errors or sample bias. These processes were
Table 2. Characteristics of the 10 male stroke cases implemented in the pilot study.
Study-ID Ethnicity Age Positive Family HistoryHypertension Diabetes Smoking TOAST Stroke Type
M-006 African American 46 No No No Former Dissection
M-0114 African American 48 Yes Yes Yes Never Dissection
M-0379 African American 44 Yes No No Never Cryptogenic
M-0432 African American 42 Yes No No Current Lacunar
M-0823 African American 41 Yes Yes No Never Cardioembolic
M-1012 African American 45 Yes No No Never Lacunar
M-1096 African American 42 Yes No No Never Cryptogenic
M-1107 African American 47 Yes Yes No Never Lacunar
SW-393 Caucasian 57 Yes Yes No Never Lacunar
SW-708 Caucasian 61 Yes Yes No Former Lacunar
doi:10.1371/journal.pone.0035591.t002
Rare Variants in Ischemic Stroke
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35591parallelized using a high-performance Sun Grid Engine computer
grid, which contains more than 1000 cores and five terabytes of
available RAM. Further analysis of the resulting sequence reads
were performed using our human exome analysis pipeline based
upon the Burrows-Wheeler Aligner (BWA), and the Genome
Analysis Toolkit (GATK) [21–23]. This process is summarized in
Figure 1.
Initial alignment to the human reference genome (hg18) using
BWA was followed by statistical analyses that calculated the
percent of reads uniquely mapping, the percent of properly paired
reads, and statistics that evaluate the exome capture efficiency.
These included percent of mapped reads within targeted regions
and within a single library-fragment-length of targeted regions (+/
2200 bp). We also calculated coverage of targeted regions and
percent of targeted regions that met multiple coverage criteria (56,
206,3 0 6). The resulting alignments were stored in BAM file
format and we then used the Samtools package to identify and
remove sequence reads that resulted from duplication of library
fragments. These duplicated library fragments were artifacts of the
necessary PCR step in library construction and are easily identified
by having the same start and stop position in the alignment.
Typical rates of duplication ranged between 10–20%. Removal of
these duplicated reads prevented artificially high coverage and
quality calculations and reduced false-positive variant calling.
Because Illumina quality scores tend to be over-inflated, after
removal of PCR duplicate reads, the Genome Analysis Toolkit
[22] performed a quality recalibration of each sequence read using
locally aligned reads relative to the reference genome. The
algorithm finds positions in the alignment where the sequenced
base does not concur with the reference and builds an empirical
probabilistic error model. Positions with known variants included
in dbSNP (build 130) are ignored to minimize their contribution to
basecall error calculations. Following this quality recalibration, the
root mean square error (RMSE) is significantly reduced, indicating
a high correlation between quality values modeled by GATK and
observed quality. The quality-recalibrated data is then checked for
indel positions where mis-alignments are frequent. The GATK re-
aligner performs localized multiple-sequence-alignments to reduce
these mis-alignments and thereby reduce errors in downstream
variant detection.
Following these data quality control and pruning steps, variant
detection (SNPs and indels) was performed using samtools. SNPs
are called using a stringent set of quality criteria, including a
minimum SNP quality score greater than 50, an allele balance less
than 0.75, and a maximum of two SNPs within any 10 bp
window. SNPs passing these quality criteria and falling within the
targeted capture regions are stored in VCF format and annotated
according to the RefSeq genes and isoforms in which they are
found. The SNPs are further annotated according to classification,
including coding-synonymous, missense, nonsense, intronic, UTR-
59 and UTR-39. These classifications can be made at the isoform
level to detect variants with differing potential functional impact
on alternatively spliced gene products.
The analyzed exome data set, including both VCF and BAM
files, can be visualized using the Broad Institute Integrated
Genomics Viewer (http://www.broadinstitute.org/igv/ - accessed
2010 July), which enables display of tracks including read
alignments, coverage levels, and SNP calls from multiple samples
simultaneously alongside gene annotations. This provides a
powerful tool for detailed comparative analysis between samples.
Final data included raw sequence files, alignment files, SNP
databases, and Integrated Genomics Viewer visualization.
Exome Analyses
For clarity, and to avoid replication of descriptive text, we will
sequentially describe our exome analytical methods with the
associated results in the Results section.
Results
Source population
The GEOS and SWISS study populations served as the source
population from which the 10 exome samples were selected. On
the basis that the 8 of the 10 exome samples were from the GEOS
study and that GEOS GWAS analyses were used to guide some of
our exome analyses (to be described), additional information
regarding the GEOS population is included here. The GEOS
study population includes 1816 participants, consisting of 889
cases and 927 controls with the population characteristics
demonstrated in Table 1. The mean age is 41.3 years for cases
Figure 1. Summary of the pipeline steps.
doi:10.1371/journal.pone.0035591.g001
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composed of two self-reported race groups, European-Americans
(54.5%) and African-Americans (40.4%), with the remaining 5.1%
of individuals comprising other races including Chinese, Japanese,
other Asians and other unspecified. There were more males than
females among both cases and controls. Cases were more likely
than controls to report having prevalent hypertension, diabetes
and myocardial infarction and being current smokers.
The characteristics of the 10 selected cases for exome
sequencing are listed in Table 2. While the overall goal of our
10 exome pilot was to demonstrate feasibility (i.e. capture,
sequencing, bioinformatics, data management, etc.) and obtain
pilot data for a potential larger project, we were also cognizant
that this data provided the opportunity to develop and institute our
analytic methods; albeit on a small case-only sample.
Human Exome Capture & Illumina Sequencing Methods
and Statistics
As described, we captured and sequenced ten stroke exomes. To
evaluate the efficiency and success of our targeted capture and
high-throughput sequencing of all human exons, we constructed
paired-end Illumina sequencing libraries from whole human
genomic DNA extracted from our ten clinical samples, using
Agilent’s SureSelect 37 Mb All Exon Kit to capture exonic DNA
fragments [3], and sequenced each library using a single flowcell
lane on a 75 bp paired-end Illumina run. The sequencing
generated an average of 25.5 million read pairs (75 bp62) and
3.8 Gbp per sample. We performed whole-genome alignments of
the sequence reads using BWA [21,24] against UCSC Human
Genome build 18 (NCBI build 36.1) and evaluated the exome
capture method using these results. An average of 97% of reads
from each sample aligned uniquely and 96% of paired reads were
properly mated based on orientation and distance. The sequenc-
ing and alignment statistics are demonstrated in Table 3.
Though the targeted capture method enables a high rate of
enrichment for the targeted regions, non-specific capture also
occurred. In our pilot samples, an average of 55% of aligned reads
mapped to the targeted regions of the genome and 71% mapped
onto or within 200 bp of the targeted regions. These rates of
successful capture meet or exceed the expectations set by previous
studies [3,20]. Because of the high rates of exon capture efficiency
and sequence mapping, the average depth of coverage per
targeted region was 596 and less than 1% of exons went
uncaptured. More than 80% of targeted exons exceed 206
coverage, which serves as a typical lower limit for high-confidence
SNP calling algorithms using Illumina short-read sequence data.
These high-quality and consistent data demonstrate the efficacy of
the targeted capture and sequencing using the Illumina platform
within the Genomics Resource Center and will serve as the basis
for further refinement of the data pipeline and analysis methods.
Data cleaning and SNP Calling Pipeline
After sequencing, our data went through several data cleaning
and alignment steps in preparation for SNP calling; these
procedures were explained in the Methods. The application of
these methods to our 10 exomes resulted in SNP calling as denoted
in Table 4. After applying quality filters, African-Americans
showed greater variation with an average of ,24.5 K variants
compared to ,22.4 K for Caucasians as expected from the
literature; the number of variants (not in dbSNP) was 2839
(11.6%) vs.1105 (4.9%), respectively. Although we have predicted
the indels, we have not yet analyzed them.
To further evaluate the quality our data we sought publically-
available exome (genome) data that could be used for comparison
purposes. Here it is important to note that while one might
consider utilizing only publically-available unaffected control
reference data for comparison with our case-only exome data,
such methods may introduce unbeknownst errors. While such
methods may be appropriate when studying rare Mendelian
diseases that express a highly-defined phenotype, complex diseases
by nature have a less well-defined phenotype, with the genetic
contribution to any specific complex disease being un-established
across any potential publically-available control population. As
such we propose that unaffected matched controls to the cases
under evaluation be utilized along with the publically available
control data, then statistically evaluating for differences in the
controls population prior to case-control comparisons. In our pilot
study no matched controls were utilized, however 3 appropriate
Table 3. Sequencing and Alignment Statistics for Ten Stroke Exomes.
Sample ID M006 M0114 M0379 M0432 M0823 M1012 M1096 M1107 SW393 SW708
Total Reads (75/76 bp) in
millions(rounded)
43,863,768 37,155,698 40,247,747 39,894,677 34,450,161 41,907,790 39,676,183 34,271,695 40,443,932 44,516,721
Mapping % 98.18% 96.64% 98.10% 95.69% 97.41% 96.58% 96.49% 97.34% 98.30% 98.48%
Good pairs % 97.50% 96.01% 97.12% 94.90% 96.90% 95.89% 95.79% 96.92% 97.75% 98.08%
Singletons % 0.55% 0.53% 0.66% 0.74% 0.45% 0.65% 0.65% 0.39% 0.49% 0.32%
% reads in targeted regions 49.74 53.92 54.10 54.94 61.36 59.61 55.54 53.34 49.97 54.65
% reads in targeted regions +/
2100 bp
64.55 66.54 65.77 61.80 69.39 67.09 61.96 60.48 60.39 65.07
% reads in targeted regions
+/2200 bp
71.14 72.78 71.21 66.80 74.93 72.46 66.88 65.18 65.18 69.84
Overall coverage of target region 42.66 38.586 42.566 41.456 41.026 39.626 42.376 43.016 43.65 43.26
% of targeted baits with
.206coverage
76.84 75.26 79.22 78.20 78.56 77.13 78.25 77.98 78.67 76.83
% of targeted baits with
.306coverage
64.37 57.81 65.88 64.07 63.60 61.15 65.06 64.98 66.37 65.29
% of baits with no reads aligning 0.76 0.56 0.44 0.62 0.70 0.71 0.67 0.72 0.49 0.95
doi:10.1371/journal.pone.0035591.t003
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These included 61 African Ancestry individuals from the
Southwest US (ASW), 100 Yoruba (Ibadan, Nigeria (YRI)) and
116 Caucasians of Western European ancestry (CEU), all of which
were sequenced as part of the 1000 Genomes Project (http://
www.1000genomes.org/about - accessed 2011 July). Comparisons
of all SNPs identified in our 10 exome study subjects and those
within the same exomic regions from subjects within the 3 controls
populations are seen in Figure 2 and denoted in the first line of
Table 5. In summary, there is an overlap of 41936 SNPs among
the 4 populations (of note these are not unique SNPs, but are SNPs
that appear at least once in any individual in the population). Our
cumulative exome data (all 10 subjects) demonstrates 53766 SNPs
that were not seen in any of the control populations (see Figure 2).
Many of these SNPs are shared across our case samples.
Comparing our exome data with these pre-existing reference
populations highlights several key points. First, our data has
significant overlap with these datasets, highlighting the quality of
our exome data. Second, the overlap between our data and the
various populations is incomplete, demonstrating that there are
numerous previously unidentified variants in our exomic dataset.
Third, the two differing African-American control populations
have incomplete overlap, emphasizing the need to use well-
matched controls (to the cases); implementing principal compo-
nent and ancestry informative marker analyses will minimize
confounding secondary to population admixture.
As a final evaluation of the quality of our exome data we
compared our exome genotype calls with the available fixed
GWAS content [18] genotype calls of the 8 GEOS study subjects.
These results are detailed in Table S1. In summary, there were
29600 exonic SNPs in the GWAS data; call comparisons
demonstrated a concordance rate of ,99% across the 8 subjects.
Analyses of the 10 Stroke Exomes
We spent considerable time and effort optimizing our SNP
calling algorithms pipeline (see Methods), with the results of
several different analyses utilizing our 10 pilot case exomes now
presented.
Gene–Specific Analyses
Pursuant to our hypothesis that excess rare variation may play
an important role in gene-specific stroke risk, we decided to
evaluate specific genes among our exome data. Before we could
embark on such analyses, control data was required and was
obtained as described above. Two sets of genes were chosen for
these analyses. The first were the genes containing the ‘‘top’’
lacunar stroke coding variants as identified by our GWAS study
and the second were a series of candidate genes selected from the
literature [25–27].
The ‘top’ lacunar stroke coding variants from our GWAS results
were identified by sorting our lacunar stroke specific results
(lacunar stroke cases vs. all controls) by p-value smallest to largest.
This was performed in the pooled sample and by ethnicity
(African-Americans and Caucasians). Our hypothesis was that
while none of these common variants reached genome-wide
significance, maybe these gene-specific variants were marking
stroke susceptibility genes and that potentially unknown excess
rare-variation could also play a role. To be clear, we do not believe
that common variation is marking rare variation, but hypothesize
that potentially a combination of common and rare variation in
these genes may work together to increase risk. Utilizing our
GWAS results [18] for lacunar stroke subtype we screened for the
1000 smallest p-values from each of the 3 groups (pooled sample
and by ethnicity (African-Americans and Caucasians)), then
further screening each list to identify the nonsynonymous coding
SNPs present. This was performed implementing SIFT [28]
(http://sift.jcvi.org/www/SIFT_dbSNP.html - accessed 2010
July) which identified the nonsynonymous coding SNPs (missense
only; no stop codons were seen) and also rated the variants as
deleterious or not. Among the pooled, African-American and
Caucasian groups respectively, 17, 14 and 17 missense variants
were identified; of these 4, 3, and 2 were considered to be
deleterious, inducing amino acid changes purported to affect
protein function. We then identified the genes containing these
variants. Of note, there were no SNP (or gene) overlaps between
the two ethnicities. Table 5 shows the identified genes.
The candidate genes selected for our second set of analyses were
chosen on the basis that they harbor common genetic variants
associated with ischemic stroke that have positively replicated in
Table 4. SNP Summary for SNPs in target exome regions only.
SAMPLE ID M006 M0114 M0379 M0432 M0823 M1012 M1096 M1107 SW393 SW708
SNP’s 31,990 31,097 31,756 31,255 32,368 31,385 30,942 31,595 26,472 26,942
#SNPs in dbSNP 27,364 26,887 27,506 26,260 27,139 26,198 26,045 26,797 24,116 24,509
Pass Q Filters 28,103 26,844 28,205 26,668 28,022 26,787 26,449 27,574 23,262 23,697
Pass QF and in dbSNP 25,097 24,486 25,370 23,899 24,935 23,830 23,674 24,651 22,182 22,567
Pass QF and Novel 3,006 2,358 2,835 2,769 3,087 2,957 2,775 2,923 1,080 1,130
Indels 8,313 6,033 6,583 4,750 4,909 5,193 4,737 4,823 5,214 5,599
doi:10.1371/journal.pone.0035591.t004
Figure 2. SNPs in the 10 cases exomes vs. 3 control
populations.
doi:10.1371/journal.pone.0035591.g002
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part of our GWAS [18]. These genes are listed in the lower
portion of Table 5 and include: MTHFR, F5, F2, ITGB3,
ITGA2, LTA, SERPINE1, ACE, ApoE, NOS3, and NINJ2.
Gene-based analysis of our 10-case exome data for both sets of
genes (‘top’ GWAS lacunar hits and Candidate) as compared to
the control populations were then initiated. Of note, we felt a
combined analysis (8 African-American and 2 Caucasian) was
appropriate given our limited number of exomes and pursuant to
the hypothesis that shared risk mechanisms may exist across
ethnicities. First, we screened the exome data of our cases to
identify both the known (common and rare) and novel (rare)
variants in the coding regions of each gene, followed by a
screening comparing variant counts and overlap between our data
and the control populations as shown in Table 5. Assuming that
excess variation in a gene may play a role in risk, from these data
we calculated the non-common-SNP density per Kb by gene (i.e.
(total exome variants - shared variants across all 4 populations)/
exon base-pairs) of which HLA-DPB1 and CSN3 (e.g. 10-3=7; 7/
1.312 Kb=5.34/Kb) had the greatest values. Given the expected
high variability of HLA genes, only CSN3 (Kappa-Casein) SNPs
were further evaluated. Among the ten CSN3 SNPs in the exome
data, three were previously unidentified as per dbSNP, each with
an allele count (AC) of 5% (i.e. 1 in 20). Notably, two of these three
SNPs were classified as non-synonymous annotated using the
VcfCodingSnps tool developed at University of Michigan (http://
genome.sph.umich.edu/wiki/VcfCodingSnps - accessed 2010
July). Of the remaining seven established SNPs (i.e. in dbSNP),
three were not seen in any of our control groups; corresponding
ACs of 15%, 5%, and 5%. Of the remaining four SNPs seen in
both the exome and control data, two are also non-synonymous
SNPs both with AC=5%; one is intronic with AC=5%; the last is
synonymous with AC=20%. Overall, these allele counts are
similar to the minor allele frequency as seen in the Control groups
if present. We are currently having several International Stroke
Genetics Consortium (ISGC) collaborators (http://www.
strokegenetics.org/ - accessed 2011 July) evaluate their GWAS
data with respect to this gene.
Compound Heterozygote Analyses
Pursuing the hypothesis that stroke susceptibility genes may be
enriched for novel variants across cases, we screened the exome
data for genes in which every case had a least one rare variant.
This methodology identified 70 gene isoforms where each African-
American case had at least one rare variant, with this number
dropping to 48 when the 2 Caucasian cases were also included.
Taking this a step further by implementing a ‘‘double-hit
hypothesis’’ (i.e. compound heterozygote) to evaluate for two
novel variants in the same gene isoform, only 6 genes (9 total
isoforms) satisfied this criterion. Three of the six genes identified
are involved in various forms of metabolism (AQP7, CTBP2,
ARSD), and of these, one was previously associated with diabetes
(AQP7). Of the three remaining genes, one is involved in the
inflammatory response (HLA-A), one is solely expressed in the
CNS (OR4C3), and the function of the last is unknown (FRG2C).
CTBP2 had three isoforms identified while ARDS had two.
Counting the number of novel mutations (2 or more) per each
gene isoform per sample is shown in Table 6.
Our first impression of these numbers was that they seemed
high. Nevertheless, we continued our analyses to further classify
these variants by type as demonstrated in Figure 3. In this figure
the variants per sample (x-axis) are classified by type (right y- axis)
and per gene isoforms (left y-axis). Notably, two of the CTPB2
isoforms (NM_001329 and NM_ 001083914) were seen to have a
non-sense codon occurring in all 10 samples.
Exploring these two CTPB2 isoforms, the same variant in all 10
samples was identified occurring at basepair position 126717592
resulting in T to A substitution [TTT, TTA] and a LYS to
nonsense codon in position 8 of the protein. This CTBP2 region is
graphically demonstrated in Figure 4 (using the Broad Institutes’
Integrated Genomics Viewer (IGV) (http://www.broadinstitute.
org/igv/ - accessed 2010 July), which displays the read alignments,
coverage levels, and SNP calls from multiple samples simulta-
neously (3 in this case) alongside gene annotations. Pertinent to our
CTBP2 data, we see that in the three sample tracks shown the
aligned sequence coverage demonstrates the T to A substitution
resulting in the nonsense codon as compared to the two bottom
tracks showing the annotated RefSeq and codon position. While
finding a novel stop codon among our cases would be a highly
important finding, we believed that this finding is due to non-
specific capture of a non-exome region that has a similar sequence
to our exome region of interest, in other words this is a gene-
duplication artifact. In explanation, all the cases were heterozygote
at this location. Further, the A–C haplotype as seen in Figure 4
indicates two novel SNPs (codon 7 and 8), however upon screening
dbSNP both of these SNPs have been identified in the whole
genome sequence of a Korean and in dbSNP (http://www.ncbi.
nlm.nih.gov/projects/SNP/snp_ref.
Table 6. Genes in which at least two variations which are novel.
Sample ID
Gene/Isoform M006 M0114 M0379 M0432 M0823 M1012 M1096 M1107 SW393 SW708
OR4C3/NM_001004702 6 4 4 4 3 5 4 10 4 5
CTBP2/NM_001083914 8 7 5 10 7 8 9 7 7 9
FRG2C/NM_001124759 7 6 8 7 5 8 6 8 11 7
AQP7/NM_001170 6 8 11 8 7 6 8 4 6 7
CTBP2/NM_001329 8 7 5 10 7 8 9 7 7 9
ASRD/NM_001669 10 9 9 9 9 10 7 11 11 11
HLA-A/NM_002116 6 5 7 7 8 6 2 4 3 5
ASRD/NM_009589 9 9 9 9 9 10 7 11 11 11
CTBP2/NM_022802 6 6 3 7 5 7 7 6 5 8
doi:10.1371/journal.pone.0035591.t006
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on the rs numbers one finds that ‘‘Lee’’ submitted both
rs76555439 and rs78849795 - accessed 2011 January). Further
evaluating Figure 4 one can see that there is a SNP with 3 base
variations at the far right, this finding would not be impossible, but
would be unusual. Note that the indel is perfectly correlated with
the C allele. Lastly, Mendelian diseases tend to be highly
heterogeneous in causal alleles, as seen in the recent exome
success stories. Finding the same causal allele for a complex disease
across both ethnicities and among the various stroke subtypes
evaluated would be very unusual. As such, here we mention a few
observations and potential conclusions regarding this specific
finding. First, we detected a duplication in the genome that is
either not annotated or picked up by the current alignment/
unique mapping filter. This duplication is probably monomorphic
A/A and C/C at the first two sites, but appears to have perfectly
correlated SNPs at the indel and C/G site. This nonsense
mutation would not have shown up as novel if filtered by current
dbSNP, but the mutation would have been picked up filtering by
genes with nonsense mutations in (multiple) cases. When filtering
missense/nonsense SNPs by dbSNP it might be useful to be able to
filter by allele frequency; If ND (not determined) then potentially
keep. As dbSNP is more regularly updated with exome and whole
genome data, then filtering will require care as a stroke variant
may be present in a subject from a non-stroke study.
Discussion
Our exome capture, sequencing, and analyses are among the
first to examine for the presence and affect of rare variation in
ischemic stroke. Given that the optimal methodologies regarding
exome analyses are not fully-established in the study of complex
disease, including stroke, we developed a variety of analyses to
examine our exome data. First, pursuant to our hypothesis that
excess rare variation may play an important role in gene-specific
stroke risk, we evaluated specific genes chosen based upon our
predominant stroke subtype, lacunar stroke, and also by selecting
genes based upon prior candidate gene studies. The exomic
analyses informed upon by our lacunar stroke GWAS results
identified two genes, CSN3 and HLA-DPB1, which appeared to
have excess variation in our stroke cases. Further analyses of CSN3
are ongoing; however given the expected high variability of HLA
Figure 3. Compound heterozygotes in exome data for genes in which every case had a least two novel variants in the same gene
isoform, only 6 genes (9 total isoforms) satisfied this criterion. The figure illustrates the 9 isoforms (left y-axis) per sample (x-axis) by variant
type (left y-axis). Notably, two of the CTPB2 isoforms (NM_001329 and NM_ 001083914) were seen to have a non-sense codon occurring in all 10
samples.
doi:10.1371/journal.pone.0035591.g003
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previously identified candidate genes studied demonstrated
‘excess’ rare variation in our exome samples. A compound
heterozygote analyses pursuant to the hypothesis that stroke
susceptibility genes may be enriched for novel variants across cases
was also performed, identifying several genes with rare variation
across all 10 cases. In particular, CTPB2 appeared to contain a
nonsense codon that appeared in all 10 cases, however after
further analyses this was identified as a false positive. As a pilot
study we identified several important methodological consider-
ations and pitfalls that should be considered when implementing
such methods. First, we emphasize the importance of selecting a
highly defined phenotype among the study subjects, such as
selecting on one stroke subtype, few established vascular risk
factors, and positive a family history of stroke. Further selecting the
study subjects in the extremes of the phenotypic tail (i.e. young-
onset stroke) may also further maximize the genetic contribution to
stroke risk. Second, as our results demonstrate, investigators must
evaluate for the presence of potential false positive findings, a
major pitfall regarding this type of research. Utilizing existing
databases for non-diseased control samples may be fraught with
difficulties as a control populations ascertained to study a different
disease may contain an individual with the disease under study (in
this case stroke). When studying rare variation, introducing such
an error would be particularly troublesome.
While our gene specific analyses failed to identify excess rare
variation in any of the ischemic stroke candidate genes evaluated,
ouranalysesevaluatingourexomedata inconsiderationofourprior
GWAS results identified one gene, kappa-casein (CSN3), which
warrants additional discussion. As described, by screening our prior
GWAS results for genes containing coding SNPs in lacunar stroke,
and then evaluating the implicated genes in our exome data, we
identified CSN3 (OMIM: 601695; http://omim.org/entry/601695
- accessed 2011 July) as containing an interesting coding
polymorphism as well as containing excess rare variation. CSN3
maps to chromosome 4 at 4q21.1 and contains 5 exons covering
8.85 kb on the direct strand from position 71108305 to 71117153
(NCBI 37, August 2010). The predicted protein has 182 aa
(20.3 kDa, pI 8.1). While the function and tissue expression pattern
of this gene is are not fully established, Kappa-casein is known to
stabilize micelleformationpreventing caseinprecipitationinhuman
breast milk (http://www.genecards.org/ - accessed 2011 July).
Expression studies have demonstrated the presence of kappa-casein
in a variety of soft tissue/muscle tissue cancers [29] and also in
coronary artery atherosclerosis [30]. In the coronary atherosclerosis
study, the investigators performed a comprehensive gene level
expression assessment of coronary atherosclerosis using 51 coronary
artery segments isolated from the explanted hearts of 22 cardiac
transplant patients, demonstrating that CSN3 was consistently
highly expressed in all arterial segments analyzed.
Other studies have indicated that kappa-casein may play a role
in immune and inflammatory responses via regulation of the
transcription factor nuclear factor kappaB (NF-kappaB) [31].
Activation of NF-kappaB requires the activity of IKK, a kinase
complex that contains two catalytic subunits, IKKalpha and
IKKbeta, and a regulatory subunit IKKgamma. In one such
study, the investigators worked to understand how IKK activity
was regulated, and searched for IKKgamma-interacting proteins
Figure 4. This image shows the start region for CTPB2 gene (chromosome 10) in the Integrated Genomics Viewer. The top three tracks
show aligned sequence coverage for three of the pilot exomes and demonstrate the T to A substitution resulting in the nonsense codon as compared
to the two bottom tracks showing the annotated RefSeq and codon positions.
doi:10.1371/journal.pone.0035591.g004
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component of the COP9 signalsome, as a protein specifically
interacting with IKKgamma. Over-expression of CSN3 inhibited
NF-kappaB activation triggered by tumor necrosis factor (TNF),
but not interleukin-1 (IL-1). Moreover, over-expression of CSN3
also inhibited NF-kappaB activation triggered by proteins involved
in TNF signaling, including TNF-R1, TRAF2, RIP, and NIK, but
not by TRAF6, a protein involved in IL-1 signaling. These data
suggest that CSN3 is a specific negative regulator of TNF- but not
IL-1-induced NF-kappaB activation pathways.
CSN3 was also identified as a novel candidate genes for type 2-
diabetes mellitus (T2-DM) in a genome-wide association scan in the
Old Order Amish [32]. In this study of 124 type 2 diabetic case
subjectsas compared with 295 controlsubjects,CSN3SNPrs3775745
was found to be associated with T2-DM in the Amish (p=0.002),
with this result replicating in a Mexican-American population
(p=0.003). Of note, none of our exome study subjects had diabetes.
Exome based approaches offer different, yet complimentary,
information to ongoing stroke genome wide association study
(GWAS) efforts, including ongoing projects implementing sub-
stantially larger samples sizes as compared to our GWAS sample.
While we are optimistic about the success of GWAS to identify
stroke associated variants, we do not believe that GWAS results
will account for all stroke risk. This point of view was recently
supported by the results of a Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium
GWAS study evaluating ischemic stroke risk in which only 2
intergeneic SNPs were found to achieve genome-wide significance
[27]. In the CHARGE study, SNP rs12425791 on chromosome
12p13 was associated with an increased risk of ischemic stroke with
a hazard ratio of 1.33 (95% CI, 1.21 to 1.47), yielding a population
attributable risk of 12%. A corresponding hazard ratio of 1.42
(95% CI, 1.06 to 1.91; p=0.02) was attained in a large follow-up
cohort of black subjects. While these results were extremely
important, they did not demonstrate that a few common variants
account for the majority of stroke risk. Furthermore, our research
group and several other groups participating in the ISGC failed to
replicate the findings of the CHARGE study, thereby calling into
question the validity of the CHARGE results [33].
While genome-wide association studies (GWAS) can identify
common variants, they are not suited for situations where genetic
architecture is such that multiple rare disease-causing variants
contribute significantly to disease risk. This is because GWAS
chips most often implement common variants as identified
through the HapMap project and these variants do not serve as
markers for rare variation [34]. As such, we believe that
sequencing will ultimately identify rare risk variants and that
exome sequencing, given its ability to identify rare variants of high
penetrance, is an excellent methodology to begin these efforts.
Large scale exome projects are now well underway, most notably
including the National Heart, Lung, and Blood Institute (NHLBI)
GO Exome Sequencing Project (ESP). The ESP is funded by
NHLBI and managed by both NHLBI and National Human
Genome Research Institute (NHGRI). The goal of the ESP is to
develop and validate a cost-effective, high-throughput sequencing
application for all protein coding regions of the human genome in
the study of several diseases, including ischemic stroke. The
purpose of developing this resequencing application is to enable
the sequencing of tens of thousands of individual samples from
NHLBI’s well-phenotyped populations in a cost-effective manner.
These data will be publically-available and free to use by the
scientific community. Among these there will be a deeply
phenotyped reference sample not selected on basis of disease,
consisting of 750 Caucasians of European origin and 250 African-
Americans. The first samples have recently been submitted to
dbGaP with many more over the next year.
Our pilot study has several limitations. Most notably the small
samplesizewhichwasdirectlyattributabletothecostsassociatedwith
exome sequencing. Further, given that stroke is a prototypical
complex disease with numerous risk factors and subtypes, the genetic
mechanisms of each stroke (by subtype) included in our study is likely
somewhat different. However, as described in the Methods section,
we worked to limit the presence of risk factors in our young-stroke
onset samples. Our study was also hampered by a lack of
standardized analysis programs for exome analysis. At present the
analytic methodologies regarding rare-variant analyses are an area of
active methodological research [35]. While there were certainly
many different potential analyses that could be performed on our
dataset, we focused our efforts on what we felt might yield the ‘low
lying fruit’; that is, non-synonymous coding variants leading to
missense or nonsense mutations. This was motivated by the fact that
overhalfofall known disease mutationscomefromsuch replacement
polymorphisms; such an assumption may or may not be appropriate
in the setting of ischemic stroke. Here we also highlight that our
definition of ‘‘non-common variants’’ refers to variants that are not
shared between the exome data and the combined 3 control
populations. For example, a shared variant between the African-
American control data (YRI or ASW) and the 8 African-American
exome cases, that was not seen in the Caucasian control data, would
be considered ‘‘non-common’’. The reasoning for formulating our
definition in this fashion was that we were seeking a shared gene-
specific stroke mechanism across ethnicities rather than an ethnicity
specific mechanism. In other words, we were seeking global excess
variation among the cases in the genes evaluated as compared to
control population as a whole. While it would certainly be interesting
to perform an ethnicity stratified analyses, we felt that our current
sample size precludes such analyses. Another important analysis issue
we considered is the potentially confounding effect of population
substructure which could induce false-positive (or false negative)
findings. Implementing PLINK [36,37] on our GWAS data allowed
us to identify 47 population outliers who were removed from the pool
considered for our exome analyses. Lastly, by including African-
Americans in our exome analyses we inherently complicated our
study. While there is little data available on the allelic spectrum of the
exome in African-Americans, HapMap data has shown up to a 2 fold
greater number of SNPs in the Yoruba (Ibadan, Nigeria) (YRI) same
set samples compared to the Caucasians (CEU). However, given the
fact that African-American adults are twice as likely to have a stroke
as their Caucasian adultcounterparts [38], with this especially true in
the young [39,40], we felt that the additional scientific opportunity
offset the additional exome complexity inherent when studying
African-Americans.
Our study also has several advantages. First, our study population
is an ideal sample to evaluate since young age-of-onset is an extreme
phenotype that is likely enriched with rare variants; further
supported by the fact that numerous familial aggregation studies
implicate a greater genetic risk at younger ages. Another strength is
that our exome samples were also genotyped on the Illumina 1 M
Quad [Omni Quad] as part of our groups’ participation in the
GENEVA consortium [41], thereby allowing us to perform the
combined exome and GWAS analyses as described. Of note, our
GWAS data was rigorously evaluated by the GENEVA Data
Cleaning Group (University of Washington, Seattle, WA) and the
genotyping center, the Center for Inherited Disease Research
(CIDR) (http://www.cidr.jhmi.edu/ - accessed 2011 July). Quality
metrics include missing genotype call rates by sample and SNP,
Hardy-Weinberg analysis, and detailed global and local population
substructure analysis using principle components analysis [18].
Rare Variants in Ischemic Stroke
PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e35591In closing, our study evaluated a highly prevalent complex
disease for which the genetic architecture remains uncertain. Prior
and ongoing studies implementing genome-wide association
techniques are only capable of identifying common variants
associated with disease. The extent to which ischemic stroke is
determined by rare or low frequency variants has not yet been
explored. Our study demonstrates the feasibility of utilizing exome
based techniques to address this important research gap by
implementing several different analyses at the variant and gene
levels. Our study also highlights several of the important
considerations in this type of research, such as attaining a highly
specific phenotype and utilizing an extreme phenotype that is
likely enriched with rare variants; in our case young-onset subtype-
specific stroke. One gene, CSN3, identified by screening our prior
GWAS results for genes containing coding SNPs in lacunar stroke,
was found to both contain an interesting coding polymorphism as
well as excess rare variation in our exome data as compared with
the other genes evaluated. Additional research will be required to
determine if CSN3 variants are truly associated with ischemic
stroke risk. Lastly, while rare coding variants may predispose to the
risk of ischemic stroke, this fact has yet to be definitively proven.
Our study demonstrates the complexities of such research and
highlights that while exome data can be obtained, the optimal
analytical methods have yet to be determined.
Supporting Information
Table S1 Call rate concordance between overlapping exome
and GWAS SNPs.
(DOC)
Author Contributions
Conceived and designed the experiments: JWC OCS JFM BDM SJK
JRO. Performed the experiments: XL AP LJT LKS. Analyzed the data:
JWC XL AP LJT LKS ND YC JRO. Contributed reagents/materials/
analysis tools: XL AP LJT LKS ND YC. Wrote the paper: JWC OCS
MAW BJS JFM BDM SJK JRO.
References
1. Minin ˜o AM, Xu JQ, Kochanek KD (2010) Deaths: Preliminary Data for 2008.
National Vital Statistics Reports; 59 no 2. Hyattsville, MD: National Center for
Health Statistics.
2. American Heart Association: Heart disease and stroke statistics–2009 update
(2009) Circulation 119: e21–e181.
3. Agilent Technologies: http://www.opengenomics.com/Products/SureSelect_
Human_Exon_Kit Accessed 2010 July.
4. Botstein D, Risch N (2003) Discovering genotypes underlying human
phenotypes: past successes for mendelian disease, future approaches for complex
disease. Nat Genet 33: 228–237.
5. Ng PC, Levy S, Huang J, Stockwell TB, Walenz BP, et al. (2008) Genetic
Variation in an Individual Human Exome. PLoS Genetics 4(8.
6. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, et al. (2009) Exome
sequencing identifies the cause of a mendelian disorder. Nature Genetics
2009:42: 30–5.
7. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, et al. (2009)
Targeted capture and massively parallel sequencing of 12 human exomes.
Nature 461: 272–6.
8. Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, et al. (2008) Rare independent
mutations in renal salt handling genes contribute to blood pressure variation.
Nature Genetics 40: 592–9.
9. Lesage S, Lohmann E, Tison F, Durif F, Du ¨rret A, et al. (2008) Rare
heterozygous parkin variants in French early-onset Parkinson disease patients
and controls. Journal of Medical Genetics 45: 43–46.
10. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, et al. (2003)
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson
disease. Neurology 60: 796–801.
11. Brass LM, Page WF, Lichtman JH (1998) Stroke in twins III: a follow-up study.
Stroke 29 Suppl: 256.
12. Hassan A, Markus HS (2000) Genetics and ischaemic stroke. Brain 123:
1784–1812.
13. Schulz UG, Flossmann E, Rothwell PM (2004) Heritability of ischemic stroke in
relation to age, vascular risk factors, and subtypes of incident stroke in
population-based studies. Stroke 35: 819–824.
14. MacClellan LR, Howard TD, Cole JW, Stine OC, Giles WH, et al. (2006)
Familial aggregation of ischemic stroke in young women: The Stroke Prevention
in Young Women Study. Gen Epid 7: 602–8.
15. Kittner SJ, Stern BJ, Wozniak M, Buchholz DW, Earley CJ, et al. (1998)
Cerebral infarction in young adults: the Baltimore-Washington Cooperative
Young Stroke Study. Neurology 50: 890–894.
16. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993)
Classification of subtype of acute ischemic stroke. Definitions for use in a
multicenter clinical trial. TOAST. Trial Org 10172 in Acute Stroke Treatment.
Stroke 24: 35–41.
17. Meschia JF, Brown RD, Jr., Brott TG, Chukwudelunzu FE, Hardy J, et al. (2002)
TheSiblingsWithIschemicStrokeStudy (SWISS)protocol.BMC MedGenet3:1.
18. Cheng YC, O’Connell JR, Cole JW, Stine OC, Dueker N, et al. (2011) Genome-
wide association analysis of ischemic stroke in young adults. G3: Genes,
Genomes, Genetics 1: 505–514.
19. Agilent Technologies 2009 – Product notes: http://www.chem.agilent.com/
Library/brochures/5990-3532en_lo%20CMS.pdf Accessed 2010 July.
20. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, et al. (2009) Solution
hybrid selection with ultra-long oligonucleotides for massively parallel targeted
sequencing. Nature Biotechnology 27: 182–9.
21. Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics 26: 589–95.
22. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The
Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res 20(9): 1297–303.
23. DePristo M, Banks E, Poplin R, Garimella K, Maguire J, et al. (2011) A
framework for variation discovery and genotyping using next-generation DNA
sequencing data. Nature Genetics 43(5): 491–498.
24. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-
Wheeler Transform. Bioinformatics 25: 1754–60.
25. Matarin M, Brown WM, Dena H, Britton A, De Vrieze FW, et al. (2009)
Candidate Gene Polymorphisms for Ischemic Stroke. Stroke 40: 3436–42.
26. Xin XY, Song YY, Ma JF, Fan CN, Ding JQ, et al. (2009) Gene polymorphisms
and risk of adult early-onset ischemic stroke: A meta-analysis. Thrombosis
Research 124: 619–24.
27. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, et al. (2009)
Genomewide Association Studies of Stroke. N Engl J Med 360: 1718–28.
28. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nature
Protocols 4: 1073–81.
29. Yoneda-Kato N, Kato JY (2008) Shuttling imbalance of MLF1 results in p53
instability and increases susceptibility to oncogenic transformation. Mol Cell Biol
28(1): 422–34.
30. King JY, Ferrara R, Tabibiazar R, et al. (2005) Pathway analysis of coronary
atherosclerosis. Physiol Genomics 23(1): 103–18.
31. Hong X, Xu L, Li X, et al. (2001) CSN3 interacts with IKKgamma and inhibits
TNF- but not IL-1-induced NF-kappaB activation. FEBS Lett 499(1–2): 133–6.
32. Rampersaud E, Damcott CM, Fu M, et al. (2007) Identification of novel
candidate genes for type 2 diabetes from a genome-wide association scan in the
Old Order Amish: evidence for replication from diabetes-related quantitative
traits and from independent populations. Diabetes 56(12): 3053–62.
33. Nalls MA, Biffi A, Matarin M, Anderson CD, Chasman DI, et al. (2010) Failure
to Validate Association between Variants on 12p13 and Ischemic Stroke.
N Engl J Med 362(16): 1547–50.
34. MacArthur D, Why do genome-wide scans fail? (2008) Genetic Future, http://
www.genetic-future.com/2008/03/why-do-genome-wide-scans-fail.html Ac-
cessed 2010 July.
35. Bansal V, Libiger O, Torkamani A, Schork NJ (2010) Statistical analysis
strategies for association studies involving rare variants. Nature Reviews
Genetics 11: 773–785.
36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–75.
37. Weeks JP (2009) Plink: IRT separate calibration linking methods (R package).
http://cran.r-project.org/web/packages/plink/index.html Accessed 2010 July.
38. CDC (2007) 2006 Summary Health Statistics for U.S. Adults. http://www.
omhrc.gov/templates/content.aspx?ID=3022 Accessed 2010 July.
39. Jacobs BS, Boden-Albala B, Lin IF, Sacco RL (2002) Stroke in the Young in the
Northern Manhattan Stroke Study. Stroke 33: 2789.
40. Kleindorfer D, Broderick J, Khoury J, Flaherty M, Woo D, et al. (2006) The
Unchanging Incidence and Case-Fatality of Stroke in the 1990s: A Population-
Based Study. Stroke 37: 2473.
41. Cornelis MC, Agrawal A, Cole JW, Hansel NN, Barnes KC, et al. for the
GENEVA Consortium. The gene, environment association studies consortium
(GENEVA): maximizing the knowledge obtained from GWAS by collaboration
across studies of multiple conditions. Genet Epidemiol 34(4): 364–72.
Rare Variants in Ischemic Stroke
PLoS ONE | www.plosone.org 13 April 2012 | Volume 7 | Issue 4 | e35591